171 related articles for article (PubMed ID: 26300542)
21. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
[TBL] [Abstract][Full Text] [Related]
22. Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein.
Dhungel N; Eleuteri S; Li LB; Kramer NJ; Chartron JW; Spencer B; Kosberg K; Fields JA; Stafa K; Adame A; Lashuel H; Frydman J; Shen K; Masliah E; Gitler AD
Neuron; 2015 Jan; 85(1):76-87. PubMed ID: 25533483
[TBL] [Abstract][Full Text] [Related]
23. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
[TBL] [Abstract][Full Text] [Related]
24. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
[TBL] [Abstract][Full Text] [Related]
25. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
26. Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up.
Ishiguro M; Li Y; Yoshino H; Daida K; Ishiguro Y; Oyama G; Saiki S; Funayama M; Hattori N; Nishioka K
Parkinsonism Relat Disord; 2021 Mar; 84():139-143. PubMed ID: 33611076
[TBL] [Abstract][Full Text] [Related]
27. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
28. EIF4G1 mutations do not cause Parkinson's disease.
Nichols N; Bras JM; Hernandez DG; Jansen IE; Lesage S; Lubbe S; Singleton AB;
Neurobiol Aging; 2015 Aug; 36(8):2444.e1-4. PubMed ID: 26022768
[TBL] [Abstract][Full Text] [Related]
29. Role of the VPS35 D620N mutation in Parkinson's disease.
Mohan M; Mellick GD
Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
[TBL] [Abstract][Full Text] [Related]
30. The EIF4G1 gene and Parkinson's disease.
Deng H; Wu Y; Jankovic J
Acta Neurol Scand; 2015 Aug; 132(2):73-8. PubMed ID: 25765080
[TBL] [Abstract][Full Text] [Related]
31. EIF4G1 gene mutations are not a common cause of Parkinson's disease in the Japanese population.
Nishioka K; Funayama M; Vilariño-Güell C; Ogaki K; Li Y; Sasaki R; Kokubo Y; Kuzuhara S; Kachergus JM; Cobb SA; Takahashi H; Mizuno Y; Farrer MJ; Ross OA; Hattori N
Parkinsonism Relat Disord; 2014 Jun; 20(6):659-61. PubMed ID: 24704100
[TBL] [Abstract][Full Text] [Related]
32. VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.
Niu M; Zhao F; Bondelid K; Siedlak SL; Torres S; Fujioka H; Wang W; Liu J; Zhu X
Aging Cell; 2021 May; 20(5):e13347. PubMed ID: 33745227
[TBL] [Abstract][Full Text] [Related]
33. Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
Jiang M; Tu HT; Zhang K; Zhang W; Yu WP; Xu J; Tan EK; Guo KH; Zeng L
Neurobiol Dis; 2021 Jun; 153():105313. PubMed ID: 33636388
[TBL] [Abstract][Full Text] [Related]
34. Frequency of the D620N mutation in VPS35 in Parkinson disease.
Kumar KR; Weissbach A; Heldmann M; Kasten M; Tunc S; Sue CM; Svetel M; Kostić VS; Segura-Aguilar J; Ramirez A; Simon DK; Vieregge P; Münte TF; Hagenah J; Klein C; Lohmann K
Arch Neurol; 2012 Oct; 69(10):1360-4. PubMed ID: 22801713
[TBL] [Abstract][Full Text] [Related]
35. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice.
Ishizu N; Yui D; Hebisawa A; Aizawa H; Cui W; Fujita Y; Hashimoto K; Ajioka I; Mizusawa H; Yokota T; Watase K
Hum Mol Genet; 2016 Oct; 25(20):4507-4517. PubMed ID: 28173004
[TBL] [Abstract][Full Text] [Related]
36. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model.
Chiu CC; Weng YH; Huang YZ; Chen RS; Liu YC; Yeh TH; Lu CS; Lin YW; Chen YJ; Hsu CC; Chiu CH; Wang YT; Chen WS; Liu SY; Wang HL
Cell Death Dis; 2020 Nov; 11(11):1018. PubMed ID: 33257649
[TBL] [Abstract][Full Text] [Related]
37. Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation.
McGough IJ; Steinberg F; Jia D; Barbuti PA; McMillan KJ; Heesom KJ; Whone AL; Caldwell MA; Billadeau DD; Rosen MK; Cullen PJ
Curr Biol; 2014 Jul; 24(14):1670-1676. PubMed ID: 24980502
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits.
Zhou L; Wang W; Hoppel C; Liu J; Zhu X
Biochim Biophys Acta Mol Basis Dis; 2017 Nov; 1863(11):2791-2795. PubMed ID: 28765075
[TBL] [Abstract][Full Text] [Related]
39. Screening for VPS35 mutations in Parkinson's disease.
Sheerin UM; Charlesworth G; Bras J; Guerreiro R; Bhatia K; Foltynie T; Limousin P; Silveira-Moriyama L; Lees A; Wood N
Neurobiol Aging; 2012 Apr; 33(4):838.e1-5. PubMed ID: 22154191
[TBL] [Abstract][Full Text] [Related]
40. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
